Boothbay Fund Management’s Sage Therapeutics SAGE Stock Holding History

Boothbay Fund Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-28,800	Closed	-$1.64M	–	2150
2021 Q2	$1.64M	Buy	28,800 +28,507	+9,729%	+$2.02M	0.05%	469
2021 Q1	$2.19M	Buy	+293	New	+$24K	0.08%	290
2019 Q4	–	Sell	-192	Closed	-$2.69M	–	970
2019 Q3	$2.69M	Hold	192	–	–	0.25%	98
2019 Q2	$3.52M	Buy	192 +7	+4%	+$1.19K	0.32%	63
2019 Q1	$2.94M	Buy	+185	New	+$26.8K	0.29%	77
2018 Q4	–	Sell	-114	Closed	-$1.61M	–	857
2018 Q3	$1.61M	Buy	+114	New	+$17.6K	0.16%	123
2017 Q4	–	Sell	-249	Closed	-$1.55M	–	804
2017 Q3	$1.55M	Buy	+249	New	+$19.6K	0.26%	98

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Boothbay Fund Management's SAGE Position: Q2 2025 in Review

Boothbay Fund Management sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 1,384,465 shares — an estimated $11M sold.

Boothbay Fund Management first reported a position in SAGE in Q4 2017 and held it in 14 quarters. The position peaked at $11M in Q1 2025. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

Boothbay Fund Management reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
Boothbay Fund Management sold 1,384,465 Sage Therapeutics shares in Q2 2025, an estimated $11M.
Boothbay Fund Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 14 quarters.
Boothbay Fund Management's Sage Therapeutics position peaked at $11M in Q1 2025.
191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.